Sugi Predict

Sugi Predict / Targets / BACE1

BACE1

Beta-secretase 1 · P56817 · BACE1 on Sugi Atlas →

365,961 patent compounds predicted against BACE1, 192,443 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8794 SCHEMBL8794 1.00 20/20
SCHEMBL8961 SCHEMBL8961 1.00 20/20
SCHEMBL8962 SCHEMBL8962 1.00 20/20
SCHEMBL8994 SCHEMBL8994 1.00 20/20
SCHEMBL9058 SCHEMBL9058 1.00 20/20
SCHEMBL9061 SCHEMBL9061 1.00 20/20
SCHEMBL9062 SCHEMBL9062 1.00 20/20
SCHEMBL9166 SCHEMBL9166 1.00 20/20
SCHEMBL9288 SCHEMBL9288 1.00 20/20
SCHEMBL9829 SCHEMBL9829 1.00 20/20
SCHEMBL9702 SCHEMBL9702 0.87 20/20
SCHEMBL9516 SCHEMBL9516 0.84 20/20
SCHEMBL8630 SCHEMBL8630 0.84 20/20
SCHEMBL11567 SCHEMBL11567 0.83 20/20
SCHEMBL9409 SCHEMBL9409 0.81 20/20
SCHEMBL9410 SCHEMBL9410 0.81 20/20
SCHEMBL8699 SCHEMBL8699 0.81 20/20
SCHEMBL9869 SCHEMBL9869 0.80 20/20
SCHEMBL9232 SCHEMBL9232 0.79 20/20
SCHEMBL8595 SCHEMBL8595 0.79 20/20

Clinical trials — most relevant to BACE1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline PHASE4COMPLETED
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) PHASE4COMPLETED
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease PHASE3UNKNOWN
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain PHASE3COMPLETED
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation PHASE2/PHASE3RECRUITING
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) PHASE2COMPLETED
Development of NIC5-15 in the Treatment of Alzheimer's Disease PHASE2COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease PHASE2COMPLETED
Clinical Evaluation of Florbetapir F 18 (18F-AV-45) PHASE2COMPLETED
Effect of CT1812 Treatment on Brain Synaptic Density PHASE1/PHASE2COMPLETED
Alzheimer's Disease Acitretin Medication PHASE2COMPLETED
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) PHASE1COMPLETED
PiB PET Scanning in Speech and Language Based Dementias PHASE1COMPLETED
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY PHASE1COMPLETED
Bace1as Role in Heart Failure (BACE1AS-HF) nanCOMPLETED
Online Neuropsychological Test Validation Project With Imaging Pilot nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants nanCOMPLETED
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD) nanCOMPLETED
Epilepsy in Alzheimer's Disease: Effect on Disease Progression nanUNKNOWN
Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers nanUNKNOWN
The Swedish BioFINDER - Primary Care Study nanRECRUITING
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients nanCOMPLETED
EFFECT OF PERIODONTAL TREATMENT ON ALZHEIMER DISEASE-ASSOCIATED OUTCOMES nanENROLLING_BY_INVITATION
P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid nanCOMPLETED
Attenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BACE1 binder may also engage these)

ProteinNameSimilarity
P56819 — 1.000 P56819 →
Q2HJ40 — 1.000 Q2HJ40 →
P56818 — 1.000 P56818 →
Q1KLR6 — 0.994 Q1KLR6 →
Q8BG28 — 0.944 Q8BG28 →
Q8BFR2 — 0.942 Q8BFR2 →
Q8N475 — 0.937 Q8N475 →
Q6QNK2 — 0.934 Q6QNK2 →
Q15223 — 0.934 Q15223 →
P21214 — 0.933 P21214 →
Q10836 — 0.933 Q10836 →
P61811 — 0.933 P61811 →
Q03351 — 0.933 Q03351 →
Q5REF6 — 0.932 Q5REF6 →
Q86X52 — 0.932 Q86X52 →
Q8NCR0 — 0.932 Q8NCR0 →
Q6NRQ1 — 0.932 Q6NRQ1 →
Q38L25 — 0.932 Q38L25 →
Q5M900 — 0.931 Q5M900 →
Q90999 — 0.931 Q90999 →
P38438 — 0.931 P38438 →
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 0.931 landscape →
NTRK2 BDNF/NT-3 growth factors receptor 0.931 landscape →
Q8IWK6 — 0.931 Q8IWK6 →
Q93ZQ5 — 0.930 Q93ZQ5 →
Q6ZQ11 — 0.930 Q6ZQ11 →
P07225 — 0.930 P07225 →
LIPG Endothelial lipase 0.930 landscape →
Q9NQZ7 — 0.930 Q9NQZ7 →
P17247 — 0.930 P17247 →